Brief: Shattuck Labs - Announces Phase 1 Data For Sl-325
08/06/2026 11:03
BRIEF-Shattuck Labs - Announces Phase 1 Data For Sl-325 June 8 (Reuters) - Shattuck Labs Inc STTK.O:
SHATTUCK LABS - ANNOUNCES PHASE 1 DATA FOR SL-325
SHATTUCK LABS - ANTIDRUG ANTIBODIES TO SL-325 DETECTED IN 3.7% OF PARTICIPANTS
SHATTUCK LABS - SL-325 WELL TOLERATED WITH FAVORABLE SAFETY PROFILE
SHATTUCK LABS - NO EVIDENCE OF DR3 AGONISM OBSERVED
SHATTUCK LABS - PHASE 2B TRIAL OF SL-325 IN CROHN'S DISEASE TO START Q3 2026
SHATTUCK LABS - PHASE 1 TRIAL OF SL-846 EXPECTED TO INITIATE IN H1 2027
Source text: ID:nGNX6DMns3
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shattuck Labs
See all newsBrief: Shattuck Labs Announces Phase 2 Clinical Trial Of Sl-325 In Hidradenitis Suppurativa And Appointment Of Shoba Ravichandran, M.D., As Senior Vice President, Clinical Development
Shattuck Labs Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
U.S. STOCKS ON THE MOVE-Duke Energy, Sea, Cardinal Health